View all discussions
View all audits
please login to access my bpac
Dont have an account? Sign up here
Forgot your login? Reset password
From 1 August, 2018, rivaroxaban will be fully subsidised without restriction for people who require an oral anticoagulant.
Encouraging progress has been made by prescribers in New Zealand in reducing the use of topical antibiotics such as fusidic acid; however...
For the majority of people with upper respiratory tract infections symptomatic treatment will offer better outcomes than antibiotics,
which will not be indicated in most cases.
In general, the recommended durations of antibiotic treatment regimens are decreasing as evidence for the safety and efficacy of shorter courses accumulates.
From 1 June, 2018, aripiprazole can be prescribed without Special Authority approval, making access easier for patients who
require an alternative to other antipsychotics...
The recently released 2018 Cardiovascular Disease Risk Assessment and Management for Primary Care consensus
statement provides updated recommendations for clinicians in primary care.
An increasing incidence of early onset type 2 diabetes in New Zealand is putting more people at risk of early mortality
and complications such as cardiovascular disease at an age when other people in the community are at their prime.
Access your personalised prescribing reports
Audits are endorsed by the RNZCGP as a CQI activity for allocation of MOPS credits for General Practitioners
Quizzes are endorsed by RNZCGP for allocation of MOPS credits
Discussion points for peer groups or self-reflection of practice
Selected letters from readers with interactive feedback
Antibiotics Guide 2017 edition
Pharmacological treatment options for patients with COPD
Our next theme will be “Substance misuse”, including articles on safe prescribing of medicines with potential for misuse, alcohol use disorder and an article on hepatitis B.
Articles | Mybpac |
About | FAQ | Contact |
Permissions & reprints
Made with by the bpacnz team